 Early initiation of Selexopag, brand name, LumaCafter, has been shown to reduce the risk of disease progression and prolong overall survival in patients with pulmonary arterial hypertension, PAH, according to a recent analysis of two clinical trials. This analysis suggests that Selexopag should be used within six months of diagnosis, even if it is combined with other treatments such as combination therapy or triple therapy. This article was authored by J. Jerry Coglin, Sean Gaine, Richard Chamnick, and others.